<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Hack LM</submitter><funding>NCATS NIH HHS</funding><pagination>e2318411</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10273022</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>6(6)</volume><pubmed_abstract>&lt;h4>Importance&lt;/h4>Cognitive deficits in depression have been associated with poor functional capacity, frontal neural circuit dysfunction, and worse response to conventional antidepressants. However, it is not known whether these impairments combine together to identify a specific cognitive subgroup (or "biotype") of individuals with major depressive disorder (MDD), and the extent to which these impairments mediate antidepressant outcomes.&lt;h4>Objective&lt;/h4>To undertake a systematic test of the validity of a proposed cognitive biotype of MDD across neural circuit, symptom, social occupational function, and treatment outcome modalities.&lt;h4>Design, setting, and participants&lt;/h4>This secondary analysis of a randomized clinical trial implemented data-driven clustering in findings from the Inte</pubmed_abstract><journal>JAMA network open</journal><pubmed_title>A Cognitive Biotype of Depression and Symptoms, Behavior Measures, Neural Circuits, and Differential Treatment Outcomes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.</pubmed_title><pmcid>PMC10273022</pmcid><funding_grant_id>UL1 TR003142</funding_grant_id><pubmed_authors>Zenteno S</pubmed_authors><pubmed_authors>Schatzberg AF</pubmed_authors><pubmed_authors>Olmsted AM</pubmed_authors><pubmed_authors>Hack LM</pubmed_authors><pubmed_authors>Jubeir J</pubmed_authors><pubmed_authors>O'Hara R</pubmed_authors><pubmed_authors>Korgaonkar MS</pubmed_authors><pubmed_authors>Yesavage JA</pubmed_authors><pubmed_authors>Williams LM</pubmed_authors><pubmed_authors>Tozzi L</pubmed_authors><pubmed_authors>Hilton R</pubmed_authors></additional><is_claimable>false</is_claimable><name>A Cognitive Biotype of Depression and Symptoms, Behavior Measures, Neural Circuits, and Differential Treatment Outcomes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.</name><description>&lt;h4>Importance&lt;/h4>Cognitive deficits in depression have been associated with poor functional capacity, frontal neural circuit dysfunction, and worse response to conventional antidepressants. However, it is not known whether these impairments combine together to identify a specific cognitive subgroup (or "biotype") of individuals with major depressive disorder (MDD), and the extent to which these impairments mediate antidepressant outcomes.&lt;h4>Objective&lt;/h4>To undertake a systematic test of the validity of a proposed cognitive biotype of MDD across neural circuit, symptom, social occupational function, and treatment outcome modalities.&lt;h4>Design, setting, and participants&lt;/h4>This secondary analysis of a randomized clinical trial implemented data-driven clustering in findings from the Inte</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jun</publication><modification>2026-04-29T02:32:29.489Z</modification><creation>2025-02-19T01:20:39.076Z</creation></dates><accession>S-EPMC10273022</accession><cross_references><pubmed>37318808</pubmed><doi>10.1001/jamanetworkopen.2023.18411</doi></cross_references></HashMap>